Glaukos Corp (GKOS) Peer Comparison

$176.89

$0.20 (0.11%)

As on 23-Oct-2026 13:43EDT

Market cap

$10,422 Mln

Revenue (TTM)

$613 Mln

P/E Ratio

--

P/B Ratio

13.3

Div. Yield

0 %

Edit

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	Bio-Rad Laboratories
Market cap ($ Mln)	10,422	12,800	11,137	11,600	9,737
Revenue ($ Mln)	613	1,505	785	6,561	2,589
Net Profit ($ Mln)	-188.05	160.59	41.54	-578.00	222.40
Net Margin (%)	-30.68	10.67	5.29	-8.81	8.59
RoE (%)	-28.10	10.86	1.97	-10.33	3.04
Price to Earnings	--	79.84	240.30	--	46.15
Price-To-Book	13.27	8.22	4.93	1.77	1.36

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	Bio-Rad Laboratories
Operating Revenue	612.84	1,504.87	785.10	6,561.10	2,589.30
Cost of Revenue	127.96	483.98	384.30	4,473.00	1,245.50
Gross Profit	393.22	942.44	347.62	2,139.40	1,343.60
Operating Expenses	565.37	833.56	335.50	2,373.70	1,108.90
Operating Profit (EBIT)	-80.49	187.34	65.30	-285.60	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-192.83	203.83	52.15	-472.00	350.40
Provision for Tax	-4.79	43.24	10.61	106.00	128.00
Profit after Tax (Net Income)	-188.05	160.59	41.54	-578.00	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	Bio-Rad Laboratories
Shareholder's Funds	682.49	1,530.77	2,112.03	5,630.20	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	135.71	210.18	705.49	4,583.70	2,116.80
Current Liabilities	102.33	233.78	132.66	1,382.00	961.30
Total Liabilities	893.49	1,826.52	2,949.70	11,794.70	10,576.50

Assets ($ Mln)

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	Bio-Rad Laboratories
Non-Current Assets	404.74	630.60	1,749.63	9,133.70	7,231.50
Current Assets	515.78	1,344.12	1,200.55	2,462.20	3,020.50
Total Assets	893.49	1,826.52	2,949.70	11,794.70	10,576.50
Total Debt*	102.84	212.71	690.94	3,697.80	1,203.70
Net Current Assets	413.45	1,110.35	1,067.90	1,080.20	2,059.20

Cashflow ($ Mln)

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	Bio-Rad Laboratories
Cash From Operating Activities	-46.34	238.66	117.42	623.80	532.20
Cash Flow from Investing Activities	-77.61	-404.59	-298.47	-130.50	-189.70
Cash from Financing Activities	11.89	26.53	-15.21	-409.40	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	Bio-Rad Laboratories
ROCE (%)	-22.53	11.76	1.79	-5.43	8.98
ROE (%)	-28.10	10.86	1.97	-10.33	3.04
ROA (%)	-18.00	7.95	1.36	-4.08	2.02
EBIT Margin (%)	-30.58	13.63	9.87	-4.47	15.42
Net Margin (%)	-30.68	10.67	5.29	-8.81	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	Bio-Rad Laboratories
Revenue Growth (%)	41.55	17.55	16.49	-1.57	1.37
EBIT Growth (%)	-116.42	17.49	920.78	-129.16	-20.02
Net Profit Growth (%)	-102.66	8.72	400.42	-184.08	-30.32
EPS Growth (%)	-96.88	8.12	394.30	-184.11	-29.66
Book Value Growth (%)	-12.65	17.33	2.16	-9.82	2.19

Valuation Ratios

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	Bio-Rad Laboratories
Price / Earnings	-34.59	68.93	189.42	-14.68	--
Price / Book Value	13.27	8.22	4.40	1.77	--
Dividend Yield (%)	0.00	0.00	--	0.00	--
EV/EBITDA	-72.93	56.13	50.32	121.15	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	Bio-Rad Laboratories
Debt to Equity	0.00	0.00	0.26	0.65	0.11
Short term debt to equity ratio	0.00	0.01	0.01	0.01	0.06
Current Ratio	5.04	5.75	9.05	1.78	3.14
Quick Ratio	4.46	3.86	7.64	1.18	2.33
Interest Coverage	-38.31	157.91	1.92	-1.64	8.18

Operating Efficiency Ratios

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	Bio-Rad Laboratories
Debtors to sales (%)	22.67	12.65	20.09	17.36	17.06
Asset Turnover	0.59	0.74	0.26	0.46	0.24
Receivable days	60.95	46.54	72.41	58.79	65.39
Inventory Days	193.84	331.92	146.53	64.13	221.09
Payable days	60.19	26.16	29.05	58.13	37.02
Cash Conversion Cycle	194.60	352.30	189.88	64.79	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly